These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11107840)

  • 21. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates.
    DeLong M; Wright J; Dawson M; Meyer T; Sommerer K; Dunbar C
    J Aerosol Med; 2005; 18(4):452-9. PubMed ID: 16379620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methacholine dry powder inhaler as a new tool for bronchial challenge test.
    Colombo G; Terzano C; Colombo P; Petroianni A; Ricci A; Buttini F
    Int J Pharm; 2008 Mar; 352(1-2):165-71. PubMed ID: 18055141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
    Broeders ME; Molema J; Burnell PK; Folgering HT
    J Aerosol Med; 2005; 18(1):74-82. PubMed ID: 15741776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization.
    Heng D; Lee SH; Ng WK; Chan HK; Kwek JW; Tan RB
    Int J Pharm; 2013 Aug; 452(1-2):194-200. PubMed ID: 23680726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
    Kemp JP; Hill MR; Vaughan LM; Meltzer EO; Welch MJ; Ostrom NK
    Ann Allergy Asthma Immunol; 1997 Oct; 79(4):322-6. PubMed ID: 9357377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Inspiratory Pressures in Determining the Flow Rates Though Dry Powder Inhalers; A Review.
    Clark AR
    Curr Pharm Des; 2015; 21(27):3974-83. PubMed ID: 26290203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size.
    Coates MS; Chan HK; Fletcher DF; Raper JA
    J Pharm Sci; 2006 Jun; 95(6):1382-92. PubMed ID: 16625656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution.
    de Vries TW; Rottier BL; Gjaltema D; Hagedoorn P; Frijlink HW; de Boer AH
    Respir Med; 2009 Aug; 103(8):1167-73. PubMed ID: 19269801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parametric two-tier sequential quality assurance test of delivery dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Shen M; Lostritto RT; Poochikian GK
    J Biopharm Stat; 2008; 18(5):976-84. PubMed ID: 18781529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
    Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
    Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
    Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
    Chew NY; Chan HK
    J Aerosol Med; 2001; 14(4):495-501. PubMed ID: 11791690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary dispersion formulations: the impact of dispersed powder properties on pressurized metered dose inhaler stability.
    O'Donnell KP; Williams RO
    Drug Dev Ind Pharm; 2013 Mar; 39(3):413-24. PubMed ID: 23216244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Peak inspiratory flow generated through different analogue dry powder inhalers in Shenzhen healthy preschool children].
    Zhang QL; Zheng JP; Pan WH; He H; Chen GL; An JY; Yuan LF; Luo DF
    Zhonghua Er Ke Za Zhi; 2008 Feb; 46(2):98-103. PubMed ID: 19099680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine dry powder inhalation for bronchial challenge testing, part 1: inhaler and formulation development and in vitro performance testing.
    Lexmond AJ; Hagedoorn P; van der Wiel E; Ten Hacken NH; Frijlink HW; de Boer AH
    Eur J Pharm Biopharm; 2014 Jan; 86(1):105-14. PubMed ID: 24140941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of a novel dry powder inhaler.
    Zhang X; Ma Y; Zhang L; Zhu J; Jin F
    Int J Pharm; 2012 Jul; 431(1-2):45-52. PubMed ID: 22543053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.